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Abstract
The main predictor of outcomes in herpes simplex virus (HSV) encephalitis (HSE) is the delay between hospital admission and initiation
of acyclovir. In this study, factors associated with late initiation of acyclovir were identiﬁed. The study included adults from northern
France whose cerebrospinal ﬂuid (CSF) was positive for HSV by PCR. Late initiation of acyclovir was deﬁned as a delay of >1 day from
hospital admission. In total, 184 patients were retrospectively enrolled from January 1991 to December 2002. The median age was
60 years (range: 17–91), and 102 (55.4%) were male. Acyclovir was initiated >1 day after hospital admission in 68 patients (37.0%).
According to multivariate analysis, independent risk factors for late initiation of acyclovir were severe underlying disease (Knaus
score ‡C) (OR 4.1; 95% CI 1.5–11.7); alcohol abuse (OR 3.4; 95% CI 1.3–8.9); and a delay of >1 day from admission to ﬁrst brain
imaging (OR 8.4; 95% CI 3.9–18.0). In addition, univariate analysis suggested an association between a ﬁnding of <10 leukocytes/mm3 in
CSF at admission (OR 2.5; 95% CI 0.7–5.8). These characteristics were found in 26 (14.1%), 23 (12.5%), 66 (35.9%) and 27 (14.7%)
patients, respectively. One risk factor was identiﬁed in 109 (59.2%) patients, two in 29 (15.8%), and three in six (3.3%). Patients with
HSE often present with severe underlying disease, chronic alcohol abuse, or atypical CSF ﬁndings, and such factors should not be
allowed to delay diagnosis and administration of acyclovir.
Keywords: Herpes simplex virus, encephalitis, acyclovir, risk factors
Original Submission: 30 June 2008; Revised Submission: 19 September 2008; Accepted: 22 September 2008
Editor: E. Gould
Clin Microbiol Infect 2009; 15: 560–564
Corresponding author and reprint requests: J. Poissy, Centre
Hospitalier Dron, Service Universitaire de Maladies Infectieuses
et Tropicales, 135 rue du Pre´sident Coty, 59200 Tourcoing, France
E-mail: julien_poissy@hotmail.fr
Introduction
Herpes simplex virus (HSV) is the primary cause of viral
necrotizing encephalitis in developed countries, and leads to
a 70% mortality rate when left untreated [1,2]. Vidarabine
was the ﬁrst antiviral drug shown to decrease HSV enceph-
alitis (HSE) mortality [3]. Two large clinical trials later
showed that outcomes improved signiﬁcantly when patients
took acyclovir [4,5], and this drug has since become the
standard treatment for HSE. However, the mortality and
persistent neurological impairment associated with HSE
remain high in developed countries [6,7]: as many as 53%
of patients develop long-term neurological sequelae or die
[1].
One risk factor associated with severe morbidity and
mortality related to HSE is delayed initiation of acyclovir
[4,8,9]. In a study conducted with 93 patients with HSE,
Raschilas et al. [8] found that a delay of >2 days from admis-
sion to the hospital to initiation of acyclovir was associated
with a three-fold increase in poor outcome at 6 months, in
comparison with administration before this time. Thankfully,
unlike other risk factors associated with mortality and severe
morbidity, the time to initiation of therapy can be modiﬁed
and the prognosis for patients with HSE thereby improved.
The aim of this study was to determine the factors associ-
ated with late initiation of acyclovir in patients suffering from
HSE.
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Materials and Methods
Study design and patients
We conducted a retrospective study of 184 patients who
had been diagnosed with HSE from 1991 to 1998 and from
1991 to 2002 in the Ile de France and Nord Pas-de-Calais
regions of France, respectively. The characteristics and out-
comes of the ﬁrst 93 patients have been described elsewhere
[8]. In the current study, we ﬁrst consulted the records of
the virology laboratories at the Hoˆpital Saint-Vincent de Paul
(Ile de France region), Hoˆpital Calmette, Hoˆpital de Lens,
and PASTEUR CERBA (Nord Pas-de-Calais region). We then
consulted the medical records of patients whose cerebrospi-
nal ﬂuid (CSF) was positive for HSV DNA by PCR [10]. We
included in our study adult patients, more than 18 years old.
We used a standardized checklist to collect data retrospec-
tively from patients’ medical records. Data were extracted
by one reviewer (FR) in the Ile de France region and by two
reviewers (MB and JP) in the Nord Pas-de-Calais region.
Methods
We recorded the age, sex and history of chronic alcohol
abuse (positive when it was recorded in the medical records
of the patients, and negative when it was not speciﬁed) for
all recruited patients. We used the Knaus scale to capture
the severity of underlying diseases [11], separating them into
four categories: (A) normal health status; (B) moderate inﬁr-
mity; (C) severe inﬁrmity; and (D) bedridden. Moderate inﬁr-
mity was deﬁned as the impossibility of work or study, and
severe inﬁrmity as the need to have a third person to assist
in daily life processes. We used the MacCabe scale to evalu-
ate the prognoses of underlying diseases [12], segregating
outcomes into three categories: (0) no fatal disease; (1) fatal
disease with life-expectancy of <5 years; and (2) fatal disease
with life-expectancy of <1 year. These categories were
determined using knowledge of the prognosis of underlying
disease.
We recorded the presence or absence of the following
clinical data within the ﬁrst 24 h of admission: fever (temper-
ature above 37.8C); focal neurological symptoms, seizures,
disorientation, hallucinations, and behavioural changes. These
variables were considered to be positive when they were
recorded in the medical records of the patients, and negative
when they were not speciﬁed. The severity of neurological
impairment was evaluated using the Glasgow Coma Scale
[13].
We collected computed tomography (CT), magnetic reso-
nance imaging (MRI) and electroencephalographic proﬁles, as
well as CSF leukocyte counts and protein levels, for each
patient. We also determined the delay between hospital
admission and lumbar puncture, electroencephalography, CT
scan, and/or MRI, as well as the time elapsing from hospital
admission to acyclovir initiation.
Statistical analysis
Using descriptive analyses, we evaluated the median, minimal
and maximal values, and interquartile range (IQR), for each
continuous variable. We determined the rate of occurrence
of each event to evaluate qualitative variables.
We considered the initiation of acyclovir to be delayed
if the drug was administered ‡24 h after hospital admission.
In order to establish the factors associated with late initia-
tion of acyclovir, we ﬁrst performed univariate analyses to
determine the association of each variable with late initiation
of treatment, using a logistic model with one explicative vari-
able. We measured strength of association using ORs, and
assessed the precision of our results using a 95% CI.
We used the Wald test to assess the signiﬁcance of the OR.
We evaluated exposures for which the p value was <0.20 in
the univariate analysis with a multivariate logistic regression
model. Backward stepwise regression procedures were used
to develop a ﬁnal multivariate model that assessed the asso-
ciation of independent factors with late initiation of therapy
[14]. A p value <0.05 (two-tailed) was considered to be sig-
niﬁcant. Statistical analysis was performed using SAS software
(SAS 9.1; SAS Institute Inc., Cary, NC, USA).
Results
The median age of the 184 enrolled subjects was 58 years
(Table 1), and 102 (55.4%) of the patients were male.
A majority of patients were found to be at stage A on the
Knaus scale and at stage 0 on the MacCabe scale. At hospital
admission, the median temperature was 39C (IQR 38.4–
39.5). Fifteen per cent of patients were afebrile. Neurological
signs and symptoms consisted mainly of language impairment
(47.3%), disorientation (43.6%), seizures (36.7%), and
behavioural changes (34.9%). The median Glasgow Coma
Scale score was 14 (IQR 13–15). The median delay between
hospital admission and ﬁrst lumbar puncture was 1 day
(IQR 0–1). In initial CSF samples, the median leukocyte
count was 83.5/mm3 (IQR 21–195.5), with lymphocytes pre-
dominating, and the median protein level was 0.67 g/L (IQR
0.47–1). The leukocyte count was <10/mm3 in the initial CSF
of 15% of the patients.
The median delay between hospital admission and ﬁrst
brain imaging (CT scan or MRI) was day 0 (IQR 0–1). All
patients received intravenous acyclovir, after a median delay
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of 1 day from hospital admission to initiation of acyclovir
(IQR 0–3) (Fig. 1). Among the 181 patients for whom data
on vital status were available 6 months after hospital admis-
sion, 36 had died (19.9%). The mortality rate was 13% for
patients for whom acyclovir was initiated within 1 day of
hospital admission vs. 31% for patients for whom acyclovir
was initiated >1 day after hospital admission (p <0.02).
According to univariate analysis, patients for whom acyclo-
vir therapy was initiated ‡24 h after hospital admission were
more likely to have a history of chronic alcohol abuse
(OR 2.5; 95% CI 1.1–5.7), a higher Knaus score (Knaus
score C + D vs. Knaus score A and B; OR 2.8; 95% CI 1.2–
6.7), and a CSF white cell count <10/mm3 (OR 2.5; 95% CI
1.0–5.0), and were more frequently afebrile (OR 5.0;
95% CI 1.7–10.0). There was a longer delay between hospi-
tal admission and ﬁrst brain imaging in patients for whom
therapy was initiated later than in patients treated early
(median, 0 vs. 1; p 0.001) (Table 2).
TABLE 1. Demogaphic characteristics and baseline clinical
and laboratory ﬁndings in 184 patients with herpes simplex
virus encephalitis in northern France
Characteristic Value
Age (years), median (IQR 25–75) 58 (46–91)
Sex ratio, M/F 1.24
MacCabe score (%)
0 76.6
1 20.1
2 3.3
Knaus score (%)
A 58.2
B 27.7
C 13.6
D 0.5
Temperature (C), median (IQR 25–75) 39.0 (38.4–39.5)
GCS score, median (IQR 25–75) 14 (13–15)
Neurological signs (%)
Language disturbances 47.3
Temporal–spatial disorientation 43.6
Seizures 36.7
Behavioural changes 34.9
CSF parameters
Leukocyte count cells/mL · 103,
median (IQR 25–75)
83.5 (21.0–195.5)
Lymphocytes (%) 80.5 (58.0–95.0)
Polynuclear neutrophils (%) 4.0 (1.0–16.0)
Protein concentrationl (g/L), median (IQR 25–75) 0.67 (0.5–1)
Delay of lumbar puncture after hospitalization (days),
median (IQR 25–75)
1 (0–1)
Time to brain imaging (CT scan and/or MRI) after
hospitalization (days), median (IQR 25–75)
0 (0–1)
Time to initiation of acyclovir after hospitalization
(days), median (IQR 25–75)
1 (0–3)
CSF, cerebrospinal ﬂuid; CT, computed tomography; GCS, Glasgow Coma Scale;
MRI, magnetic resonance imaging.
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FIG. 1. Time to initiation of acyclovir in 184
patients with herpes simplex encephalitis in
northern France.
TABLE 2. Univariate analysis of factors associated with late
initiation of acyclovir in 184 patients with herpes simplex
virus encephalitis in northern France
Baseline characteristics
£1 day
(N = 116)
>1 day
(N = 68)
OR
(95% CI) p
Age (years), median 57.2 60.0 0.33
Sex (female) 44.0% 45.6% 1.1 (0.6–2.0) 0.88
MacCabe score (0) 77.6% 75.0% 0.9 (0.4–1.8) 0.69
Knaus score
A 62.0% 51.5% 1.0
B 28.5% 26.5% 1.1 (0.6–2.3) 0.75
C + D 9.5% 22.0% 2.8 (1.2–6.7) 0.02
Chronic alcohol consumption 10.3% 22.4% 2.5 (1.1–5.7) 0.03
Absence of fever 3.8% 18.0% 5.0 (1.7–10.0) 0.003
Focal neurological deﬁcit 28.2% 24.2% 0.8 (0.4–1.6) 0.60
Seizures 37.2% 35.8% 0.9 (0.5–1.8) 0.87
Disorientation 44.8% 41.7% 0.8 (0.5–1.7) 0.75
Hallucinations 10.6% 11.7% 1.1 (0.4–3.1) 0.80
Behavioural changes 38.9% 27.6% 0.6 (0.3–1.2) 0.17
Speech disturbances 52.8% 37.3% 0.5 (0.3–1.0) 0.07
CSF parameters
Leukocytes/mm3, median 89 64 0.12
Leukocyte <10/mm3 10.7% 22.1% 2.5 (1.0–5.0) 0.05
Lymphocyte proportion >50 80.8% 85.0% 1.4 (0.5–3.5) 0.64
Protein concentration
(g/L), median
0.67 0.69 0.76
Protein level >1 g/L 25.0% 26.2% 1.1 (0.5–2.2) 0.85
Time to CT scan and/or MRI
after hospital admission, median
0 1 2 (1.0–3.3) 0.001
CSF, cerebrospinal ﬂuid; CT, computed tomography; MRI, magnetic resonance
imaging.
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Multivariate analysis showed that three factors were
independently associated with late initiation of acyclovir:
chronic alcohol abuse (p 0.02), high Knaus score (C and D
vs. A and B; p 0.007), and delay in the ﬁrst brain imaging
following hospital admission (p <0.001). The risk of late
initiation of therapy increased 2.5-fold (95% CI 0.7–5.8) in
patients whose CSF white cell counts were <10/mm3;
however, this difference was not signiﬁcant (p 0.17)
(Table 3).
The proportions of patients enrolled in this study who
had a history of chronic alcohol abuse, a high Knaus score, a
CSF white cell count <10/mm3 and delayed CT scan or MRI
were 14.7% (n = 27), 14.1% (n = 26), 12.5% (n = 23), and
35.9% (n = 66), respectively. At least one of these risk fac-
tors was present in 109 (59.2%) of enrolled patients; two
risk factors were present in 29 (15.8%) patients, and three in
six (3.3%) patients.
Discussion
Late initiation of acyclovir is the most easily modiﬁable risk
factor for poor outcomes in patients with HSE. To the best
of our knowledge, the present study is the ﬁrst to have eval-
uated the factors associated with late initiation of acyclovir
in a large cohort of patients with HSE. We found, ﬁrst, that
chronic alcohol abuse and a high Knaus score, which depicts
the severity of underlying disease, were independently asso-
ciated with late initiation of therapy. Second, our study dem-
onstrated that delay between hospital admission and initial
brain imaging was independently associated with late initia-
tion. Finally, absence of fever and a CSF white cell count
<10/mm3 were more frequent in patients whose treatment
was delayed.
The 6-month mortality rate for patients with HSE, all of
whom were treated with intravenous acyclovir, was 20%.
This rate is consistent with HSE mortality rates reported in
previous studies [1,2,4,5]. The risk of death increased more
than two-fold when acyclovir was initiated ‡1 day after hos-
pital admission.
We found that chronic alcohol abuse and raised Knaus
score were independently associated with late initiation of
acyclovir. These factors may decrease the probability that cli-
nicians will consider the diagnosis of HSE initially. Indeed, if a
patient has known underlying severe disease or a history of
alcohol abuse, a physician will probably assume that the
observed neurological symptoms are caused by these condi-
tions, rather than considering encephalitis. This study sug-
gests that chronic alcohol abuse and severe underlying
disease should not obscure, or lead the clinician away from,
the diagnosis of encephalitis. In all patients with neurological
symptoms and fever, clinicians should examine the CSF and
perform brain imaging in order to detect early HSE or
another infectious encephalitis.
Although the absence of fever and CSF white cell counts
<10/mm3 were associated with late initiation of therapy in
univariate analysis, there was no statistically signiﬁcant associ-
ation in multivariate analysis. This was probably due in part
to a lack of statistical power, as the ORs for these associa-
tions, especially the low CSF white cell count–late initiation
of acyclovir association, did not change between univariate
and multivariate analyses. Therefore, doctors should not rule
out HSE in the absence of CSF pleocytosis. In this study,
15% of patients with HSE had normal CSF white cell counts
on ﬁrst evaluation. This is a sizeable proportion, and is con-
sistent with results reported in other studies [15]. More-
over, in patients whose leukocyte count is £10/mm3, the
HSV PCR may be negative when ﬁrst applied [16]. We sug-
gest starting patients on acyclovir if they have clinical or
paraclinical signs of encephalitis and if HSE is suspected, even
when the CSF appears normal.
We found that a delay in brain imaging was indepen-
dently associated with late acyclovir initiation. Although
CSF examination and MRI or CT scans should be made a
priority, queues for these tests should not result in delayed
acyclovir initiation for patients with suspected HSE. In par-
ticular, brain imaging should delay neither lumbar puncture
nor the introduction of acyclovir if HSE is suspected. Brain
imaging is now widely used to identify patients in whom
lumbar puncture should be avoided. However, patients
younger than 60 years, without a seizure within the previ-
ous week, and without focal abnormalities upon neurologi-
cal examination, have been previously identiﬁed as good
candidates for immediate lumbar puncture without brain
imaging [17]. Moreover, in patients with these risk factors
and even with mild or moderate mass effects on brain
imaging, the risk of lumbar puncture has been found to be
negligible [17].
TABLE 3. Multivariate analysis of factors associated with
late initiation of acyclovir in 184 patients with herpes
simplex virus encephalitis in northern France
Variable OR 95% CI p
Knaus score (3 vs. 1.2) 4.1 1.5–11.7 0.007
Chronic alcohol consumption 3.4 1.3–8.9 0.02
CSF leukocytes <10/mm3 (vs. ‡10) 2.5 0.7–5.8 0.17
Time to CT scan and/or MRI
after hospital admission
8.4 3.9–18.0 <0.001
CSF, cerebrospinal ﬂuid; CT, computed tomography; MRI, magnetic resonance
imaging.
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This investigation had several limitations. First, owing to
the retrospective design of the study and possible omis-
sions in subjects’ medical records, a number of patients
may have been misclassiﬁed, leading to an underestimate of
the proportion of patients exposed to risk factors for
delayed initiation, such as history of alcohol abuse. Second,
given that the reviewers who extracted data from medical
records were aware of the objectives of the study, one
may also postulate that errors in classiﬁcation of some of
the variables collected were dependent on the outcome
(late initiation or not of therapy). This might have happened
for subjective variables such as history of alcoholic abuse,
but not for objective variables such as CSF parameters or
time to brain imaging. Any such bias, however, is unlikely,
because the medical records were completed before those
who drafted them knew the design of this study. Third,
because information was only obtainable from medical
records, which often lacked detailed information related to
delays, the time to initiation of acyclovir could only
be counted in whole days, reducing our ability to estimate
the duration of delays precisely. In fact, acyclovir should be
initiated in patients with HSE within hours of hospital
admission. However, this study shows that time to initiation
was >1 day in 50% of patients and >3 days in 25% of
patients, making our estimations of delay acceptable. Finally,
our results, based on data collected in two French regions,
may not be generalizable to other areas. Our data on HSE
mortality and morbidity are consistent with data reported
by others [4–6,8,9,18], but time to initiation of acyclovir
and factors associated with late initiation of acyclovir may
differ in other settings.
In conclusion, this study shows that a large proportion of
patients with HSE receive acyclovir too late. Moreover, we
found that a history of chronic alcohol abuse, severe under-
lying disease, absence of CSF pleocytosis and a delay in the
ﬁrst MRI or CT scan were associated with late initiation of
acyclovir. Patients with HSE showing one or several of the
ﬁrst three of these characteristics were not uncommon.
Because the early administration of antiviral therapy is cur-
rently the only management strategy that can reduce mor-
bidity and mortality in patients with HSE, physicians should
be made aware of the variables associated with delayed
administration of acyclovir.
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